0001562180-24-002309.txt : 20240305 0001562180-24-002309.hdr.sgml : 20240305 20240305174025 ACCESSION NUMBER: 0001562180-24-002309 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Colvin Richard A CENTRAL INDEX KEY: 0001944069 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 24722690 MAIL ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD STREET 2: C/O BLUEBIRD BIO, INC. CITY: SOMERVILLE STATE: MA ZIP: 02145 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-03-01 false 0001293971 bluebird bio, Inc. BLUE 0001944069 Colvin Richard A C/O BLUEBIRD BIO, INC 455 GRAND UNION BOULEVARD SOMERVILLE MA 02145 false true false false Chief Medical Officer true Common Stock 2024-03-01 4 S false 6770.00 1.5276 D 118368.00 D Stock Option (right to buy) 1.56 2024-03-01 4 A false 199000.00 0.00 A 2034-03-01 Common Stock 199000.00 199000.00 D Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. The range in prices for the transaction reported on this line was $1.52 to $1.55. The average weighted price was $1.5276. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This stock option will vest over a four-year period at the rate of 25% on the first anniversary of March 1, 2024, and then in equal monthly installments for the remaining 36 months. /s/ Sydney Gaylin, Attorney-in-Fact 2024-03-05 EX-24 2 rcolvinpoa.txt POA LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Joseph Vittiglio, Sydney Gaylin and Christopher Krawtschuk, and each of them individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) Complete and execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or ten percent (10%) shareholder of bluebird bio, Inc., a Delaware corporation (the "Company") any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual or on behalf of the undersigned's company or partnership, as the case may be, pursuant to Section 13 and Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or the rules and regulations thereunder; (2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such instruments, certificates or documents required to be filed pursuant to Sections 13 and 16 of the Exchange Act or the rules or regulations thereunder and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of October 24, 2023. /s/ Richard A. Colvin Richard A. Colvin